par Vanbaelen, Thibaut;Tsoumanis, Achilleas;Florence, Eric;Van Dijck, Christophe;Huis In 't Veld, Diana;Sauvage, Anne Sophie;Herssens, Natacha;De Baetselier, Irith;Rotsaert, Anke;Verhoeven, Veronique;Henrard, Sophie ;Van Herrewege, Yven;Van den Bossche, Dorien;Goffard, Jean-Christophe ;Padalko, Elizaveta;Reyniers, Thijs;Vuylsteke, Bea;Hayette, Marie-Pierre;Libois, Agnès ;Kenyon, Christopher
Référence The Lancet HIV, 11, 4, page (e233-e244)
Publication Publié, 2024-04-01
Référence The Lancet HIV, 11, 4, page (e233-e244)
Publication Publié, 2024-04-01
Article révisé par les pairs
Résumé : | Guidelines recommend screening for Neisseria gonorrhoeae and Chlamydia trachomatis at three anatomical sites (urethra, anus, and pharynx) every 3 months (3 × 3) in men who have sex with men (MSM) and transgender women taking HIV pre-exposure prophylaxis (PrEP). We present the first randomised controlled trial to compare the effect of screening versus non-screening for N gonorrhoeae and C trachomatis on the incidence of these infections in MSM and transgender women taking PrEP. |